Septerna Alternatives & Competitors
12 companies similar to Septerna — Bringing a new era of GPCR medicines to patients with its Native Complex Platfor...
Companies similar to Septerna
Arrakis Therapeutics
Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to...
Waltham, United States
Regor Therapeutics Group
We aspire to be a world class innovative drug discovery company from China.
Shanghai, China
Rgenta Therapeutics Inc.
We unlock the therapeutic potentials of highly disease-relevant targets undruggable by sma...
Woburn, United States
Zai Lab
Delivering innovative, transformational outcomes to patients around the world
China
Rival Readout
Competing with Septerna? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
PharmEnable Therapeutics
Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innova...
Cambridge, United Kingdom
Response Pharmaceuticals
A Clinical Stage (Phase 2) biopharmaceutical company developing treatments for weight mana...
Click Therapeutics, Inc.
Develops and commercializes software as prescription medical treatments for people with un...
New York, United States
Congruence Therapeutics
From Topology to Treatments.
Montreal, Canada
Esperion
Creative execution for today and life-saving innovation for tomorrow
Ann Arbor, United States
Tvardi Therapeutics
Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
Houston, United States
Glyscend Therapeutics
Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Ob...
Lowell, United States
About Septerna
Septerna, founded in 2022, is a biotechnology and pharmaceutical company headquartered in the United States. With the slogan, "Bringing a new era of GPCR medicines to patients with its Native Complex Platform™," the company is pioneering innovations in the GPCR landscape. Septerna aims to transform the potential of GPC...
Discovery of GPCR-targeted drug candidates, Development of oral small molecule therapies, Optimization of GPCR drug targets
Patients with unmet medical needs, Healthcare providers, Medical researchers, Pharmaceutical investors
GPCR Medicines, Native Complex Platform, Small-molecule Drugs, Drug Discovery, Biochemical Advances, Structural Drug Development, Computational Drug Discovery, Pharmacology, High-impact Medicines, G Protein-coupled Receptors, Medicinal Chemistry, Innovation In Healthcare, Patient-centric Solutions, Bioscience Research
B2B, D2C, Platform
Licensing, Performance Based, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Septerna: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Septerna on 15 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 25 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
